Insights
We offer personalized insights and strategy, and spotlight data in a compelling way to shape policy, communicate value, secure reimbursement, and drive patient access.
Reports
-
MMA IRA Payer Insights Survey
Magnolia Market Access has just released its fourth IRA Payer Insights Survey. This chartbook provides an overview of findings from the 34 payers and actuaries surveyed and interviewed regarding the future Medicare Drug Price Netoriation Program, Part D Redesign, and the Medicare Prescription Payment Program.
-
Gauging how healthcare payers and pharmaceutical manufacturers are reacting to the Inflation Reduction Act of 2022
Magnolia engaged pharmacy directors, medical directors, and actuaries at health plans and PBMs to understand how payers are designing their plan offerings and adjusting their formularies in the coming years.
-
Gathering early perceptions of payer response to the Inflation Reduction Act of 2022
Magnolia Market Access surveyed medical and pharmacy directors at health plans and pharmacy benefit managers to understand how the IRA will affect the future of the pharmaceutical industry and access to care.
-
Gathering early perceptions of payer response to the Inflation Reduction Act of 2022: Medicare Part D Redesign
Magnolia Market Access surveyed medical and pharmacy directors at health plans and pharmacy benefit managers to understand how the IRA will affect the future of the pharmaceutical industry and access to care.
-
Enhancing Oncology Model (EOM) Fact Sheet
Download to see features of the new healthcare delivery model and value-based care payment system for oncology practices, administered by the Centers for Medicare and Medicaid Services (CMS).
-
Enhancing Oncology Model (EOM) White Paper: Perspectives from Oncology Practices and the Path Forward in Value-Based Care
To gather early perceptions of the EOM and understand how oncology practices evaluated participation decisions in the new model, Magnolia facilitated an advisory panel discussion with key opinion leaders.
Case Studies
-
Building a Comprehensive Go-To-Market Strategy Through Stakeholder Ecosystem Mapping
A mid-size client was preparing for a product launch and needed assistance facilitating a successful go-to-market strategy. The company sought to identify and understand the entire stakeholder landscape and create short- and long-term stakeholder engagement strategies to meet the needs of their entire organization.
-
Market Access Segmentation & Identification
A biopharma company engaged Magnolia Market Access and sister company, 81qd, to collect data and segment provider and payer entities to identify key decision makers for a novel cardiology treatment.
-
Using EMR Data to Support Budget Impact Modeling
A large pharmaceutical company needed to demonstrate the potential cost savings of placing a new drug on payer formularies.
-
Calculating Adherence in the Presence of Variable Follow-Up
A small-size pharmaceutical company was interested in using real-world evidence to compare adherence between two formulations of an oral oncology treatment for Multiple Myeloma (MM).
-
Using Real-world Data to Support Product Label Change
A mid-size pharmaceutical company was interested in obtaining real-world evidence demonstrating the safety and effectiveness of higher dosage chemotherapy for a labeled oncology indication.
-
Identifying the Market, Business and Reimbursement Potential for Cell Therapies
Magnolia was asked to assess which type of cell therapies and disease states offered the greatest potential for development, and also wanted to further understand the benefits of creating an autologous or allogeneic product.
-
Optimal Pricing Model Identification
A new, oral formulation of an existing infused product offered better adherence and less waste, but it was uncertain if these benefits would change payer, provider, and patient pain points or critical success factors for the product’s pricing strategy.
-
Understand Perceptions of Your Hub Program
A company wanted to understand if user perceptions of the hub had improved after implementing changes. Patients and providers previously expressed dissatisfaction with services offered by company’s hub (confusing process, eligibility criteria, who to communicate with), and they recently relaunched the program with enhanced services, a customer portal, and redefined roles for client facing teams.
-
Developing a Comprehensive Launch Plan
Magnolia was engaged as a payer agency of record for a mental health digital therapeutic. Although the company had experience launching drugs in the U.S. market, the novelty of the digital therapeutic space was challenging, and the company did not have experience in mental health, nor a comprehensive launch plan in place across channels.
-
Magnolia’s Compendia Submission Helped Client Obtain Payer Coverage
Magnolia to evaluated the likelihood that a drug compendia would support an off-label dose for a drug with an FDA-approved maximum dose, and helped the client obtain stronger payer coverage with a compendia submission.
-
Patient Risk Assessments × Deep 6 AI
A client needed to develop an algorithm to identify patients at risk for chronic obstructive pulmonary disease (COPD) exacerbations via structured and unstructured EHR data to help clinicians optimize treatments. Magnolia was able to identify patients more precisely through Deep6 AI data than existing algorithms that use claims data alone.
-
Assessing the Implications of Financial Requirements on Commercial Copay Assistance Program
A medium pharmaceutical company was launching a new oral drug in the diabetes space and wanted to understand how having specific income criteria for their commercial copay program would affect patient enrollment and the costs of program operation.
-
Telling a Value Story
A biopharma company engaged Magnolia to develop a value story for an orphan-designated treatment for an auto-immune disorder that was in Phase III development. The company’s product had a novel mechanism of action in comparison to the existing agents in development and would be the first new agent for the disease in years.
-
Payer Intelligence to Gather Feedback and Understand Potential Coverage and Reimbursement of an AI CVD Technology
A small technology company developed an AI-assisted platform that is used to improve accuracy of a CV diagnostic tool. The company asked Magnolia to gather payer feedback on clinical evidence for the platforms and provide insights on future coverage and reimbursement.
-
Launch planning in an ever-evolving policy and regulatory landscape
A development-stage biopharma company engaged Magnolia to help understand the impact that the IRA would have on their product development strategies.
-
Developing the appropriate regulatory strategy for a patient-centric, therapy-agnostic app
A biopharma company engaged Magnolia to assess both the regulatory process as well as the likelihood of uptake of a therapy-agnostic phone app to support the patient journey for a rare pulmonary disease.
-
Using payer and age mix as the basis for developing a go-to-market strategy for a prelaunch drug
A biopharma company prepping to launch a biosimilar needed to know payer segments and patient age demographics.
-
Providing program management support in the lead-up to NDA submission and launch
A development-stage biopharma company engaged Magnolia to help put in place an overarching launch road map for a drug that had just received positive phase 3 data.
-
Designing a coding gameplan for a soon-to-launch infused biologic
A biopharma company needed an inpatient coding analysis for their new medication.
-
Realigning the Hub
A pharmaceutical company offering a hub designed to address patient medication access challenges received customer feedback expressing dissatisfaction from both patients and providers.
Posters/Publications
-
Linking EMR With SDOH Data: Insights Across Disease Cohorts
AMCP Spring 2024 Platinum Poster.
-
Social Determinants of Health in a Real-World Adult HIV Population: ICD-10-CM and Consumer Linked Data Identification
AMCP Spring 2024.
-
Payer Insights Survey: Gathering Early Perceptions of Health Plan Response to the Inflation Reduction Act of 2022
AMCP Spring 2024 Silver Poster.
-
Learnings from Linking Closed Claims Patient Cohorts with Consumer SDOH Data
ISPOR Spring 2024.
Presentations
-
Objection Handling: How Should Manufacturers Evolve to Meet the Clinical and Contracting Demands of Payers?
Navigating Market Access with Magnolia Summer 2024 Presentation.
-
Linking EMR With SDOH Data: Insights Across Disease Cohorts Presentation
AMCP Spring 2024 Platinum Poster and Presentation.